Biotech Breakthroughs — 2026-07-16

Top Breakthroughs This Week

1. Merck Achieves Regulatory Milestone with First Oral PCSK9 Inhibitor

• Company / Institution: Merck & Co.
• What happened: FDA approved Merck's first-in-class oral PCSK9 inhibitor—a departure from the injectable monoclonal antibodies (alirocumab, evolocumab) that have dominated the PCSK9 market since 2015. The approval represents a shift in treatment convenience and patient compliance.
• Indication / Target: High cholesterol (hyperlipidemia); patients at risk for cardiovascular events.
• Why it matters: Oral PCSK9 inhibitors eliminate the need for regular injections, potentially expanding the addressable patient population and improving medication adherence. This therapeutic class modality change could reshape competitive dynamics in the $10+ billion cardiovascular market and incentivize patients to switch from injectables.

3 sources

statnews.com

statnews.com

statnews.com

statnews.com

statnews.com

Celebrating a new, faster path to gene-editing medicines on demand

2. Multiple FDA Approvals in Oncology and Immunology

• Company / Institution: Regulatory actions across multiple sponsors (including isatuximab-irfc for multiple myeloma, and anti-cancer agents).
• What happened: FDA granted approvals for isatuximab-irfc (Sarclisa) subcutaneous formulation for multiple myeloma indications and cleared three drugs for multiple myeloma, IgA nephropathy, and bladder cancer within a 7-day window.
• Indication / Target: Multiple myeloma, IgA nephropathy, bladder cancer.
• Why it matters: The subcutaneous formulation of isatuximab expands patient convenience and reduces infusion burden. The concentrated approval pace in oncology and immunology reflects strong clinical-stage pipelines and regulatory appetite for incremental advances in high-burden disease areas.

3. Strong IPO Momentum in Oncology and Immunology

• Company / Institution: Parabilis (and 12 other venture-backed biotech IPO candidates in 2026).
• What happened: Six of 13 venture-backed biotechs to price IPOs in 2026 are focused on cancer or immune conditions. Parabilis alone raised $670 million in its June 2026 IPO debut—the largest biotech IPO of the year to date.
• Indication / Target: Cancer and immune-mediated disorders (various clinical-stage programs).
• Why it matters: The concentration of IPO capital in oncology and immunology signals sustained investor confidence in these therapeutic areas. With 13 biotech IPOs already completed in 2026, the sector is demonstrating robust access to public capital—a sharp reversal from the 2022-2024 funding drought that plagued smaller biotechs.

Regulatory Roundup

• Isatuximab-irfc (Sarclisa) subcutaneous formulation — FDA approved new subcutaneous presentation for multiple myeloma, expanding patient convenience and reducing infusion time burden.

• Three-drug oncology and nephropathy wave — FDA cleared agents for multiple myeloma, IgA nephropathy, and bladder cancer in rapid succession during the week of July 9–16. This reflects strong Phase III datasets and regulatory prioritization of oncology and immunology.

• FDA proposes hub-and-spoke manufacturing rule — Regulatory update to modernize drug manufacturing oversight and enable distributed production models for certain drug classes, supporting supply chain resilience.

Therapeutic Modality Watch

Gene & Cell Therapy

No major gene or cell therapy approvals or late-stage trial readouts reported this week. Earlier reports on CRISPR umbrellas trials and CAR-T platforms remain in the pipeline, but no fresh 7-day data available for this section.

Small Molecules & Biologics

• Merck oral PCSK9 inhibitor — First-ever oral small-molecule PCSK9 inhibitor approved, shifting the treatment paradigm away from injectable monoclonal antibodies and potentially opening the market to millions of additional patients with high cholesterol.

• Subcutaneous monoclonal antibody formulations — Isatuximab-irfc joins a growing category of mAbs transitioning to subcutaneous administration, improving tolerability and compliance in oncology.

Platform & Discovery Tech

No major AI-driven discovery or novel delivery platform announcements reported in the past 7 days.

Business & Pipeline Moves

• Biotech M&A reaches 7-year high — 38 acquisitions recorded in the first half of 2026, with nearly two-thirds valued at $1 billion or more. This represents the strongest M&A pace since at least 2019, signaling consolidation and strategic repositioning across the sector.

• Oricell Therapeutics pre-IPO round — Chinese biotech raised $110 million in "pre-IPO" financing led by Vivo Capital and others, with plans to list publicly in the near term. This follows a $70 million Series C1 in January 2026.

• Kardigan cardiovascular IPO pipeline — Kardigan Therapeutics has set plans for a $320 million IPO to fund its clinical-stage cardiovascular drug pipeline, expected to launch in the coming months.

• 13 biotech IPOs completed YTD 2026 — Venture-backed biotechs have priced 13 initial public offerings so far in 2026, including five of the six largest new biotech stock offerings since 2022. Cancer and immunology companies account for nearly half.

Analyst Take

• Dominant theme this week: Oncology and immunology IPO surge + cardiovascular modality shift. The approval of Merck's oral PCSK9 and the sustained IPO momentum in oncology/immunology reflect two major trends: (1) small-molecule oral therapies are outcompeting injectables in cardiovascular care; (2) institutional capital continues to favor high-unmet-need areas (cancer, autoimmunity) over rare disease or primary care indications.

• Momentum shift: Cardiovascular is regaining investor and regulatory attention after years dominated by oncology. Merck's oral PCSK9 signals that the market will reward convenience-driven formulation advances and may create white space for next-generation assets in lipid management. Meanwhile, oncology IPO concentration (6 of 13 YTD) suggests capital allocation is tightening around lower-risk, higher-market-size opportunities.

• Risk signals: The 38 M&A deals YTD (2-thirds worth $1B+) may signal that smaller independent biotechs are struggling to access capital or achieve clinical inflection independently, driving consolidation. Watch for downstream impacts on innovation velocity if only megapharma-backed programs advance to late-stage development.

What to Watch Next Week

• Kardigan Therapeutics IPO filing or pricing announcement — Expected roadshow and SEC filings for planned $320M cardiovascular drug IPO (trigger date TBD, likely mid-late July).
• Continued Phase III readouts in oncology — Multiple major trials expected to report in Q3 2026 per the STAT Biotech Scorecard; several have potential to move stock or reshape competitive positioning.
• Regulatory decisions on pipeline drugs — FDA actions on pending PDUFA dates for cancer and immunology candidates; expect 3–5 action letters in the coming 7–10 days.

Reader Action Items

• For investors: Monitor Merck (MRK) and other major pharma for oral PCSK9 adoption and competitive launches; track Kardigan's IPO filing for exposure to cardiovascular innovation. Watch M&A deal flow: high deal count + large deal sizes may signal forced consolidation and reduced startup independence.
• For operators & scientists: Read the FDA's July 2026 drug approvals summary and the STAT Readout piece on Merck's oral PCSK9 approval to understand formulation-driven value creation. Consider how oral small-molecule approaches compete with biologic injectables in your indication.
• For patient advocates: The approval of subcutaneous isatuximab formulation expands treatment options for multiple myeloma patients; track patient feedback on tolerability vs. the IV form. Monitor IPO pipeline for new early-stage assets addressing underserved cancers and immune conditions.